U.S. Real Estate Stock News

First Financial Q1 2026 results in focus First Financial (THFF) opened 2026 with Q1 revenue of US$65.6 million and basic EPS of US$1.67, set against trailing twelve month revenue of US$258.7 million and EPS of US$6.79 that reflect a 47.2% earnings increase over the past year. Over recent periods, the company has seen revenue move from US$59.8 million in Q4 2024 to US$60.5 million in Q1 2025 and US$65.6 million in Q1 2026. Trailing twelve month EPS stepped from US$4.00 in Q4 2024 to US$4.63 in...

Why American Electric Power Company Is On Investors’ Radar American Electric Power Company (AEP) has attracted fresh attention after recent share price moves, with the stock showing gains over the past week, month and past 3 months that investors are now reassessing. See our latest analysis for American Electric Power Company. At the current share price of $135.59, American Electric Power Company’s recent momentum is clear, with a 30 day share price return of 4.22% and a 1 year total...

First Farmers and Merchants (FFMH) has kicked off Q1 2026 with total revenue of US$18.0 million and basic EPS of US$1.38, setting a clear benchmark for the rest of the year. Over recent quarters, revenue has moved from US$15.5 million in Q1 2025 to US$18.0 million in Q1 2026, while basic EPS has shifted from US$1.11 to US$1.38. This gives investors a concrete sense of how the top line and per share earnings are tracking through the cycle. Together with a trailing twelve month net income of...

PJT Partners (PJT) just combined higher Q1 2026 earnings with a large buyback announcement, giving investors fresh numbers to assess and a new capital allocation decision to factor into their views. See our latest analysis for PJT Partners. Despite the Q1 earnings beat and the US$800 million buyback announcement, PJT’s recent share price performance has been mixed. A 12.23% 1 month share price return contrasts with a 9.64% year to date decline and a 144.95% 3 year total shareholder return,...

Asbury Automotive Group (ABG) opened Q1 2026 with revenue of US$4.1b and basic EPS of US$9.88, setting a clear marker for how the year is starting after a run of quarterly results that have kept investors focused on earnings power. Over the past year, the company has seen trailing twelve month revenue move around US$18.0b while trailing EPS has ranged between roughly US$21.05 and US$28.72. This gives a sense of how the top line and per share profitability have been tracking into this latest...

Avery Dennison (AVY) has opened 2026 with Q1 revenue of US$2.3 billion and basic EPS of US$2.18, as investors weigh these headline numbers against a modest shift in profitability over the past year. The company has seen quarterly revenue move from US$2.15 billion and EPS of US$2.10 in Q1 2025 to US$2.30 billion and EPS of US$2.18 in Q1 2026. Trailing twelve month EPS sits at US$8.90 on revenue of US$9.0 billion, while net profit margin has edged from 8.0% to 7.8%. With that backdrop, the...

Kforce (KFRC) has posted Q1 2026 revenue of US$330.4 million and basic EPS of US$0.46, setting the tone for how investors parse both quarterly headlines and the trailing picture. Over the past year, trailing twelve month revenue sits at about US$1.3 billion with basic EPS of US$1.99, providing a clear view of how the latest quarter fits into the broader earnings run rate. With trailing net margin at 2.6% compared with 3.4% a year earlier, the focus now shifts to how investors weigh softer...

AllianceBernstein has already wound down its AB Arya hedge fund within its alternatives business, with 95% of liquidation proceeds expected to be returned to clients in June. The closure retires one derivatives-heavy alternatives vehicle while AllianceBernstein continues to emphasize systematic and multi-manager offerings, subtly reshaping its alternatives mix. We’ll examine how winding down the derivatives-focused AB Arya fund may influence AllianceBernstein’s existing investment...

If you are wondering whether Phillips 66's current share price lines up with its underlying value, this breakdown will help you frame what the market might be pricing in right now. The stock last closed at US$165.13, with returns of 3.6% over 7 days, a 12.3% decline over 30 days, 26.5% year to date and 61.5% over 1 year. The 3 year and 5 year returns stand at 93.9% and 141.0% respectively. Recent price moves sit against a backdrop of ongoing coverage of Phillips 66 as a large US energy...

Aflac Incorporated recently filed a shelf registration for up to US$5.93 billion in common stock, covering 51,636,945 shares. This large financing capacity comes as Aflac approaches its latest earnings release, against a backdrop of long-term dividend growth and ongoing AI initiatives. Next, we’ll examine how this substantial shelf registration, alongside expectations for improved Japan performance, influences Aflac’s investment narrative. Find 53 companies with promising cash flow potential...

For readers wondering if MasTec at around US$375 a share still offers value, or if the big move is already behind it, this article walks through the numbers so you can judge for yourself. The stock has returned 1.0% over the last week, 18.7% over the last month, 64.8% year to date, and 194.4% over the past year, with a 3-year return of 331.0% and 5-year return of 250.0%. Recent coverage has focused on MasTec's role in large-scale infrastructure and energy-related projects and how that...

AbbVie (NYSE:ABBV) reported positive Phase 3b/4 results from the SELECT-SWITCH trial, showing RINVOQ outperformed HUMIRA in rheumatoid arthritis patients who had already tried a TNF inhibitor. The study provided the first direct head to head evidence in this specific switch setting, with higher remission rates for RINVOQ and no new safety findings versus HUMIRA. AbbVie also reached a development milestone with EvolveImmune Therapeutics related to an oncology program, adding to its solid...

Q1 2026 headline numbers and what they signal for margins First Guaranty Bancshares (FGBI) opened 2026 with Q1 total revenue of US$19.5 million and basic EPS of US$0.14, while on a trailing twelve month basis it still recorded a net loss of US$49.4 million and basic EPS of US$3.34 loss. Over recent quarters, total revenue has ranged from US$19.1 million in Q4 2024 to US$19.7 million in Q4 2025. Basic EPS has swung from a US$3.01 loss in Q3 2025 to a profit of US$0.12 in Q4 2025 and US$0.14 in...

Recent share performance and what it may signal Iovance Biotherapeutics (IOVA) has seen mixed share performance recently, with a 1 day return of negative 1.2% and a 7 day return of negative 8.4%. Over the past 3 months, the shares show a 23.3% gain. Over longer periods, returns have been weaker, including a 3 year total return of negative 44.7% and a 5 year total return of negative 88.8%. This provides important context for the recent move. See our latest analysis for Iovance...

Why Marvell Technology (MRVL) is Back on Investors’ Radar Marvell Technology (MRVL) has come back into focus after a sharp share price move over the past month, with the stock showing a return of about 62% alongside strong longer term total returns. See our latest analysis for Marvell Technology. That sharp 61.5% 30 day share price return and 83.3% 90 day share price return, alongside a 161.9% 1 year total shareholder return, suggest strong momentum even after the recent 3.1% 1 day pullback...

Wave Life Sciences (WVE) has opened Q1 2026 with revenue of US$38.2 million and a basic EPS loss of US$0.13, compared with Q1 2025 revenue of US$9.2 million and a basic EPS loss of US$0.29. Over the same stretch, trailing twelve month revenue moved from US$104.9 million in Q1 2025 to US$71.8 million in Q1 2026, while trailing EPS shifted from a loss of US$0.77 to a loss of US$1.03, creating a mixed read on top line scale versus ongoing earnings pressure. For investors, the key question is...

American Tower (AMT) opened 2026 with Q1 results that included total revenue of US$2.7 billion, basic EPS of US$1.84 and net income of US$859.5 million. This comes in a year where earnings growth over the past 12 months has been negative and the net profit margin has moved from 31.9% to 23.8%. Over recent quarters the company has seen revenue hold around US$2.5 billion to US$2.7 billion, while basic EPS has ranged from US$0.78 to US$2.63. This gives a clear view of how current profitability...

Rithm Capital Q1 2026 results in focus Rithm Capital (RITM) opened 2026 with Q1 revenue of US$961.3 million and basic EPS of US$0.12, setting the tone for how the rest of the year might shape up for shareholders watching income and capital returns. The company has seen quarterly revenue move from US$693.3 million in Q1 2025 through US$1.25 billion in Q4 2024 to US$961.3 million most recently. EPS over that span ranged from US$0.07 in Q1 2025 to US$0.54 in Q2 2025 and now sits at US$0.12,...

Sysco (SYY) has just posted another set of quarterly numbers, with Q2 2026 revenue at US$20.8b, basic EPS of US$0.81 and net income of US$389m setting the tone for how investors assess the latest update. Over the past few reported periods, revenue has moved from US$20.2b and EPS of US$0.83 in Q2 2025 to US$21.1b and EPS of US$0.99 in Q1 2026, before settling at the most recent Q2 levels. This provides a clearer run-rate backdrop for the current release. With trailing net profit margins cited...

Five Star Bancorp (FSBC) opened 2026 with Q1 total revenue of US$42.4 million and basic EPS of US$0.88, supported by net income of US$18.6 million. The company has seen revenue move from US$33.9 million and EPS of US$0.63 in Q4 2024 to US$40.7 million and EPS of US$0.83 in Q4 2025. This sets up Q1 2026 against a backdrop of rising top line and per share earnings over recent periods. For investors, that combination of revenue growth and expanding earnings is closely linked to the margin story...

Ecolab (ECL) Q1 2026 earnings snapshot Ecolab (ECL) opened 2026 with Q1 revenue of US$4.1 billion and basic EPS of US$1.53, alongside trailing twelve month revenue of US$16.5 billion and EPS of US$7.44 that frame how the latest quarter fits into the broader run rate. Over the past year, the company has seen quarterly revenue move from US$3,695 million in Q1 2025 to US$4,066.1 million in Q1 2026, while basic EPS over that same period shifted from US$1.42 to US$1.53, giving investors a clear...

Parker-Hannifin (NYSE:PH) has approved an 11% increase in its quarterly dividend. The decision extends the company’s record to 70 consecutive years of annual dividend increases. This also marks 304 consecutive quarterly dividend payments to shareholders. Parker-Hannifin, trading at $962.26, is reinforcing its identity as an income-focused industrial name with this latest dividend move. The stock is up 8.3% over the past month, 7.6% year to date, and 61.1% over the past year, reflecting...

ANI Pharmaceuticals recently launched Pimozide Tablets 1 mg and 2 mg in the U.S., a generic version of Orap, entering a market with approximately US$3.10 million in annual sales based on February 2026 IQVIA data. Coming alongside the launch of Carbamazepine Extended Release Capsules, these additions expand ANI’s generic portfolio and could modestly broaden its revenue base in complex therapies. Next, we’ll examine how these new generic launches, particularly Pimozide’s entry into a niche...

If you are wondering whether Eaton's current share price fairly reflects its quality and prospects, it helps to break the story into what the market has done and what the fundamentals may justify. At a last close of US$413.07, Eaton has delivered returns of 0.8% over 7 days, 15.6% over 30 days, 26.2% year to date, 43.8% over 1 year, 148.5% over 3 years and 210.0% over 5 years, which gives useful context before looking at valuation. Recent coverage around Eaton has focused on its role in...